DURHAM, N.C., Dec. 15 /PRNewswire/ -- Aldagen, Inc. today announced that the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, Texas will be the first site for its clinical trial using Aldagen's ALDESORT® product to isolate a unique stem cell population as therapy for critical limb ischemia (CLI) patients. The co-lead investigators at Texas Heart Institute on the study will be Dr. Emerson Perin and Dr. James Willerson.
